Claritev appointed Ben Letham as a Class I director and added him to its Risk Committee effective September 14, 2026, filling a vacancy on the board. The appointment gives investors a stated board-level focus on artificial intelligence, data analysis and innovation as Claritev expands AI across its healthcare solutions.
Key Highlights
- Ben Letham’s appointment became effective September 14, 2026.
- Letham will receive compensation under Claritev’s non-employee director policy.
- Claritev issued a press release announcing the appointment on September 15, 2026.
Claritev Corp (NYSE: CTEV) appointed Ben Letham as a Class I director effective September 14, 2026, adding him to the board’s Risk Committee.
Class I Seat and Risk Committee Assignment
Letham will be compensated under Claritev’s policy for non-employee directors and will sign the company’s standard indemnification agreement. Claritev said Letham has no family relationship with any director or executive officer and no direct or indirect material interest in a transaction requiring disclosure under applicable securities rules. The company issued a press release about the appointment on September 15, 2026. Letham currently serves as a research scientist and has worked on AI, optimization systems, digital experimentation and applied data analysis.
AI Expertise Added to Board Strategy
Claritev said Letham’s experience is intended to support its long-term strategic objectives and innovation initiatives. The company said it is deploying more AI across its solutions to help clients address complex Business challenges. Its platform uses analytics and AI to support affordability, price transparency, network design and benefits design.
FAQs
Q: Who joined Claritev’s board of directors?
A: Ben Letham joined Claritev’s board as a Class I director. He was also appointed to the board’s Risk Committee, with both roles effective September 14, 2026.
Q: What does Ben Letham bring to Claritev?
A: Letham brings experience in artificial intelligence, optimization systems, large-scale digital experimentation and applied data analysis. Claritev linked his expertise to its innovation and development initiatives.
Q: How many healthcare customers and users does Claritev serve?
A: The article does not specify how many healthcare customers or users Claritev serves. It discusses Claritev’s platform using analytics and AI to support affordability, price transparency, network design and benefits design.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.